Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis

Abstract Background Eplerenone and spironolactone, recognized as mineralocorticoid receptor antagonists (MRAs), have been reported to improve clinical prognosis among individuals diagnosed with heart failure (HF). However, the difference in the clinical effects between eplerenone and spironolactone...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Ahmed Elshahat, Ahmed Mansour, Mohamed Ellabban, Ahmed Diaa, Atef Hassan, Ahmed Fawzy, Omar Abdulrahman Saad, Moaz Abouelmagd, Mahmoud Eid, Ahmed Elaraby, Mohamed Hamouda Elkasaby, Ahmed Abdelaziz
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2024-09-01
Serie:	BMC Cardiovascular Disorders
Soggetti:	Mineralocorticoid receptor antagonist MRA Eplerenone Spironolactone Heart failure
Accesso online:	https://doi.org/10.1186/s12872-024-04103-7
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!